← Back to patent-cliff list
Ricorfotide vedotin
Tier C — Watch / tradeRicorfotide vedotin
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：Tubulin, TRPV6, FOLR1
Indications (approved)：Ovarian cancer, Breast cancer, Peritoneal cancer, Epithelial ovarian cancer, Fallopian tube cancer, Solid tumour
Regional status
US
-
EU
-
China
Phase III
2025-07-18
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ricorfotide vedotin?
Approved indications include: Ovarian cancer, Breast cancer, Peritoneal cancer, Epithelial ovarian cancer, Fallopian tube cancer, Solid tumour.
When does the Ricorfotide vedotin patent expire?
No public expiry year is available for Ricorfotide vedotin yet; this page updates once verified.
How do I get a quote for Ricorfotide vedotin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01